In vivo efficacy of voriconazole therapy in an invertebrate model of Aspergillus fumigatus infection

A. Forastiero*, L. Bernal-Martinez, E. Mellado, E. Cendejas-Bueno, M. Cuenca-Estrella, A. Gomez-Lopez

Author address: 

(Majadahonda, ES)


Objective: To investigate whether the greater wax moth Galleria mellonella is an alternative model to assess the in vivo efficacy of voriconazole (VOR) against different strains of Aspergillus fumigatus. Methods: A total of 180 larvae of G. mellonella in the sixth instar larvae were inoculated with 105 cfu/larva of different A. fumigatus strains, including parental strain (wild type for the gene encoding the azoles target cyp51A, MICVOR 0.5 mg/L) and five isogenics mutants with altered cyp51A which confer changes in antifungal drugs susceptibility (MICVOR ranging between 0.25 and 4 mg/L, EUCAST methodology). Within 120 minutes after infection, different doses of VOR were administrated. The doses used were calculated taking into account the therapeutic dose in humans and the MIC values of strains studied. Additional control groups of 50 larvae were also included (untouched, pierced, inoculated with PBS; toxicity control of antifungal and DMSO/water). Larvae were incubated at 37C and the larval survival was monitored daily considering that the larvae die when they do not respond to touch. Each experiment was performed three times. Survival data were plotted using the MantelCox tests (GraphPad Software Inc) and comparisons between untreated and treated groups were assessed with the Long Rank test (p

abstract No: 


Full conference title: 

22nd European Congress of Clinical Microbiology and Infectious Diseases
    • ECCMID 22nd (2012)